Apnimed Submits AD109 FDA Filing After Phase 3 Cut Sleep Apnea Events 44.1%
Updated
Updated · DocWire News · Jun 2
Apnimed Submits AD109 FDA Filing After Phase 3 Cut Sleep Apnea Events 44.1%
2 articles · Updated · DocWire News · Jun 2
AD109’s NDA is now before the FDA after Apnimed presented phase 3 data showing the once-daily oral drug beat placebo in obstructive sleep apnea, with a PDUFA decision expected in Q1 2027.
In the 646-patient SynAIRgy trial across 69 U.S. and Canadian centers, AD109 reduced apnea-hypopnea index by 44.1% from baseline versus 17.6% for placebo over 26 weeks.
The study enrolled adults who could not tolerate or refused CPAP; 35% had mild OSA, 42% moderate and 23% severe, with 18% of treated patients reaching disease resolution.
Safety remains a key hurdle: 21% of patients on AD109 discontinued because of adverse events versus 3% on placebo, with dry mouth, nausea, insomnia and urinary difficulty most common.
If approved, AD109 would become the first oral OSA therapy aimed at neuromuscular airway-collapse mechanisms rather than device-based treatment such as CPAP.
A new sleep apnea pill causes 1 in 5 users to quit. Is this a real alternative to CPAP?
With new drugs and nerve stimulators, is the dreaded CPAP mask finally becoming obsolete for sleep apnea?
Transforming OSA Treatment: AD109’s Phase 3 Data, Regulatory Progress, and Market Outlook as a First Oral Pill
Overview
AD109 is an investigational, once-daily oral pill developed by Apnimed to simplify the treatment of obstructive sleep apnea (OSA). After achieving positive results in pivotal Phase 3 trials, Apnimed plans to file a New Drug Application with the FDA in early 2026. This submission will start a comprehensive FDA review of AD109’s safety and efficacy. If approved, AD109 could become the first oral medication for OSA, offering a convenient alternative to current complex treatments. Apnimed’s exclusive rights and commitment to broad access position AD109 as a potential game-changer for patients with OSA.